Jun. 2 at 5:59 PM
$QNTM just hit a major regulatory roadblock ⚠️
The FDA placed Quantum BioPharma’s IND for Lucid-MS on clinical hold, requiring additional information before the planned Phase 2 study can proceed. The company is withdrawing previously disclosed timelines for FDA review, trial initiation, and interim data milestones while it works to address the agency’s comments.
Understand what this FDA setback could mean for the Lucid-MS program
Stock down 📉
See what Wall Street expects next 👉
https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38280&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38280
